Show simple item record

dc.contributor.authorXie, Yumei
dc.contributor.authorBagby, Taryn Rochelle
dc.contributor.authorCohen, Mark S.
dc.contributor.authorForrest, M. Laird
dc.identifier.citationXie, Y., Bagby, T. R., Cohen, M., & Forrest, M. L. (2009). Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opinion on Drug Delivery, 6(8), 785–792.
dc.descriptionThis is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Drug Delivery on 2009-08, available online:
dc.description.abstractCancer is the second leading cause of death in the US. Currently, protocols for cancer treatment include surgery to remove diseased and suspect tissues, focused radiation, systemic chemotherapy, immunotherapy and their combinations. With conventional chemotherapy, it is almost impossible to deliver anticancer drugs specifically to the tumor cells without damaging healthy organs or tissues. Over the past several decades, efforts have been made to improve drug delivery technologies that target anticancer drugs specifically to tumor cells. It has been known for over four decades that the lymphatics are the first site of metastasis for most solid cancers; however, few efforts have been made to localize chemotherapies to lymphatic tissues. Trials of several systemic targeted drug delivery systems based on nanoparticles containing chemotherapeutic agents (e.g., liposomal doxorubicin) have shown similar antitumor activity but better patient tolerance compared with conventional formulations. Animal studies have demonstrated that nanoparticles made of natural or synthetic polymers and liposomal carriers have higher accumulation in the lymph nodes and surrounding lymphatics compared to conventional intravenous therapies. This combination has the potential to both reduce nonspecific organ toxicities and increase the chemotherapeutic dose to the most likely sites of locoregional cancer metastasis.en_US
dc.publisherTaylor & Francisen_US
dc.subjectCancer diagnosisen_US
dc.titleDrug delivery to the lymphatic system: importance in future cancer diagnosis and therapiesen_US
kusw.kuauthorXie, Yumei
kusw.kuauthorBagby, Taryn R.
kusw.kuauthorForrest, M. Laird
kusw.kudepartmentPharmaceutical Chemistryen_US
kusw.oanotesPer SHERPA/RoMEO 6/12/2017: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: cross author cannot archive publisher's version/PDF General Conditions:

Some individual journals may have policies prohibiting pre-print archiving On author's personal website or departmental website immediately On institutional repository, subject-based repository or academic social network (Mendeley, ResearchGate or after 12 months embargo Publisher's version/PDF cannot be used On a non-profit server Published source must be acknowledged Must link to publisher version Set statements to accompany deposits (see policy) The publisher will deposit in on behalf of authors to a designated institutional repository including PubMed Central, where a deposit agreement exists with the repository
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record